Osteoporosis guidelines
- PMID: 12821611
- PMCID: PMC161602
Osteoporosis guidelines
Comment on
-
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAJ. 2002 Nov 12;167(10 Suppl):S1-34. CMAJ. 2002. PMID: 12427685 Free PMC article. Review.
References
-
- Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen R, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45. - PubMed
-
- Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524-8. - PubMed
-
- Evista® (raloxifene) product monograph. Toronto: Eli Lilly Canada Inc.; 2000 Jul 26.
-
- Johnston CC Jr, Bjarnason NH, Cohen FS, Shah A, Lindsay R, Mitlak BH, et al. Long-term effects of raloxifene on bone mineral density, bone turnover and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-50. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources